Stability Biologics, LLC - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended								12 Months Ended
	Sep. 30, 2017	Jan. 13, 2016	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common stock, par value (in dollars per share)			$ 0.001				$ 0.001				$ 0.001	$ 0.001
Loss on divestiture of Stability											$ 0	$ 0	$ (1,048)
Income tax provision benefit (expense)			$ (220)	$ 309	$ (42)	$ (42)	$ (27,497)	$ (650)	$ 13	$ 1,552	5	(26,582)	19,639
Change in fair value of earn-out consideration											$ 0	0	$ 3,560
Stability Biologics, LLC | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total gain on disposition	$ (500)
Loss on divestiture of Stability	(1,048)
Income tax provision benefit (expense)	500
Change in fair value of earn-out consideration	$ (12,240)
Stability Biologics, LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash payment for acquisition		$ 6,000
Equity issued for acquisition		$ 3,300
Equity issued for acquisition (shares)		441,009
Common stock, par value (in dollars per share)		$ 0.001
Debt assumed in acquisition		$ 1,800
Contingent consideration		17,500
Selling, general and administrative
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Change in fair value of earn-out consideration												$ 3,600
Selling, general and administrative | Stability Biologics, LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs incurred for acquisition		$ 1,100